Bionano Genomics, Inc.
BNGO
$3.65
-$0.05-1.35%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.46M | 8.16M | 6.07M | 7.77M | 8.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.46M | 8.16M | 6.07M | 7.77M | 8.77M |
| Cost of Revenue | 3.52M | 4.75M | 14.52M | 5.19M | 5.95M |
| Gross Profit | 2.94M | 3.42M | -8.45M | 2.59M | 2.82M |
| SG&A Expenses | 9.03M | 856.00K | 9.46M | 11.56M | 19.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.92M | 9.08M | 28.70M | 23.57M | 35.45M |
| Operating Income | -8.47M | -913.00K | -22.63M | -15.80M | -26.68M |
| Income Before Tax | -3.10M | -20.12M | -44.22M | -16.20M | -31.44M |
| Income Tax Expenses | 7.00K | 1.00K | 24.00K | 26.00K | -18.00K |
| Earnings from Continuing Operations | -3.10M | -20.13M | -44.25M | -16.22M | -31.42M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.10M | -20.13M | -44.25M | -16.22M | -31.42M |
| EBIT | -8.47M | -913.00K | -22.63M | -15.80M | -26.68M |
| EBITDA | -5.98M | 1.33M | -16.95M | -12.76M | -23.63M |
| EPS Basic | -1.15 | -12.22 | -30.92 | -14.40 | -35.75 |
| Normalized Basic EPS | -0.72 | -2.17 | -10.02 | -10.51 | -19.20 |
| EPS Diluted | -1.15 | -12.22 | -30.92 | -14.40 | -35.75 |
| Normalized Diluted EPS | -0.72 | -2.17 | -10.02 | -10.51 | -19.20 |
| Average Basic Shares Outstanding | 2.69M | 1.65M | 1.43M | 1.13M | 879.00K |
| Average Diluted Shares Outstanding | 2.69M | 1.65M | 1.43M | 1.13M | 879.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |